Ghadge A, Harke S, Khadke S, Diwan A, Pankaj M, Kulkarni O, Ranjekar P, Harsulkar A, Kuvalekar A A
Nutrigenomics and Functional Foods Laboratory, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth Deemed University, Pune-Satara Road, Pune, Maharashtra, India.
Bharati Vidyapeeth Medical College and Hospital, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India.
Exp Clin Endocrinol Diabetes. 2015 Sep;123(8):500-7. doi: 10.1055/s-0035-1554654. Epub 2015 Jul 27.
The present study analyzed the effects of antidiabetic drugs on antioxidant enzymes and liver function test (LFT) markers and their association with homeostatic model assessment of insulin resistance (HOMA-IR) in type 2 diabetic subjects.
We assessed healthy and diabetic subjects (100 each). Diabetic subjects were divided based on treatment with only metformin, metformin in combination with other antidiabetic drugs and insulin in combination with other antidiabetic drugs. LFT markers, antioxidant status and HOMA-IR were assessed in the subjects.
Superoxide dismutase activity was higher (p<0.01) while catalase activity was lower (p<0.01) in the diabetic subjects as compared to controls. Serum glutamate-pyruvate transaminase (SGPT) (p<0.01) and bilirubin (p<0.05) levels were higher in diabetic male subjects while urea (p<0.05) levels were lower and SGPT (p<0.01) levels were higher in diabetic female subjects. In male subjects consuming only metformin, a positive association between HOMA-IR and insulin (p<0.05) was seen. A positive association between HOMA-IR and glucose (p<0.01), insulin (p<0.01), SOD (p<0.01) and SGPT (p<0.05) was seen in males receiving metformin with other drugs. Interestingly, the female subjects on metformin displayed a positive association between HOMA-IR and insulin (p<0.05) only. A positive association of HOMA-IR with glucose (p<0.01) and insulin (p<0.05) was seen in females on metformin in combination with other anti-diabetic drugs.
The alterations in the antioxidant enzyme activities and liver function tests are dependent upon the gender and glycemic status of subjects while the variations in correlations of HOMA-IR with antioxidant enzymes, liver function tests and inflammatory markers are dependent on type of treatments.
本研究分析了抗糖尿病药物对2型糖尿病患者抗氧化酶和肝功能检查（LFT）指标的影响，以及它们与胰岛素抵抗稳态模型评估（HOMA-IR）的相关性。
我们评估了健康受试者和糖尿病患者（各100名）。糖尿病患者根据治疗方式分为仅使用二甲双胍治疗、二甲双胍与其他抗糖尿病药物联合治疗以及胰岛素与其他抗糖尿病药物联合治疗三组。对受试者进行LFT指标、抗氧化状态和HOMA-IR评估。
与对照组相比，糖尿病患者的超氧化物歧化酶活性较高（p<0.01），而过氧化氢酶活性较低（p<0.01）。糖尿病男性患者的血清谷丙转氨酶（SGPT）（p<0.01）和胆红素（p<0.05）水平较高，而尿素（p<0.05）水平较低；糖尿病女性患者的SGPT（p<0.01）水平较高。在仅服用二甲双胍的男性受试者中，HOMA-IR与胰岛素之间存在正相关（p<0.05）。在接受二甲双胍与其他药物联合治疗的男性中，HOMA-IR与血糖（p<0.01）、胰岛素（p<0.01）、超氧化物歧化酶（SOD）（p<0.01）和SGPT（p<0.05）之间存在正相关。有趣的是，服用二甲双胍的女性受试者中，HOMA-IR仅与胰岛素之间存在正相关（p<0.05）。在服用二甲双胍与其他抗糖尿病药物联合治疗的女性中，HOMA-IR与血糖（p<0.01）和胰岛素（p<0.05）之间存在正相关。
抗氧化酶活性和肝功能检查的改变取决于受试者的性别和血糖状态，而HOMA-IR与抗氧化酶、肝功能检查和炎症标志物相关性的变化则取决于治疗类型。
